TORONTO, ONTARIO--(Marketwired - Nov. 17, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of CYSVIEW®, a new photosensitizer for the detection and management of papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
Bladder cancer like many cancers is a life threatening disease. In Canada, it is the 4th most common cancer in men and the 12th most common cancer in women. Each year over 8,000 patients are diagnosed with bladder cancer and over 70% of these patients have Non-Muscle Invasive Bladder Cancer.
CYSVIEW® is used with blue light cystoscopy to detect papillary Non-Muscle Invasive Bladder Cancer in patients with known or suspected bladder cancer. It selectively targets tumour cells in the bladder and causes them to emit a red fluorescence against a dark blue background of healthy tissue under blue light cystoscopy. This makes the tumours easier to see and remove. Studies show that 24.9% of patients had tumours that were detected by CYSVIEW® with blue light cystoscopy which were not detected by the current standard of care.
This improved detection of bladder cancer tumours gives doctors a better ability to remove the tumour. This results in lower rates of cancer recurrence and increased time to the next recurrence.
CYSVIEW® has been approved by Health Canada and is also approved across Europe (branded as Hexvix®) and the U.S. (branded as CYSVIEW®). It is recommended by the European Association of Urology (EAU), the U.S. treatment guidelines on NMIBC, and a number of expert panels because of the benefit it brings to treating cancer. "BioSyent is proud to bring this innovative technology to Canada to help doctors better detect and manage bladder cancer" said René Goehrum, President and CEO of BioSyent. "This marks a further step in executing against our mission to source and market innovative pharmaceutical products that improve the lives of Canadian patients and support the healthcare providers that treat them."
CYSVIEW® has been studied extensively with 5 multi-centre Phase III studies in the U.S., Europe and Canada and has over 100 additional studies published in peer reviewed journals globally.
To learn more about CYSVIEW® please see www.biosyent.com/cysview/ or visit the product website at the following link: www.cysview.ca
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 13,966,195 shares issued and outstanding.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.